Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

4D 150

Drug Profile

4D 150

Alternative Names: 4D-150

Latest Information Update: 09 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4D Molecular Therapeutics
  • Class Eye disorder therapies; Gene therapies; Small interfering RNA
  • Mechanism of Action Gene transference; Placenta growth factor inhibitors; RNA interference; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor B inhibitors; Vascular endothelial growth factor C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic macular oedema
  • Phase I/II Wet age-related macular degeneration
  • Preclinical Diabetic retinopathy

Most Recent Events

  • 03 Feb 2024 4D Molecular Therapeutics intends to conduct additional FDA and EMA interactions in the second quarter of 2024
  • 03 Feb 2024 Efficacy and adverse event data from phase I/II PRISM trial in Wet age-related macular degeneration released by 4D Molecular Therapeutics
  • 03 Feb 2024 4D Molecular Therapeutics plans a pivotal phase III trial for Wet age-related macular degeneration in USA (Intravitreous, Injection) in Q1 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top